The CSL share price is a sleeping dividend giant. Here's why

CSL shares aren't considered serious dividend payers. But this could be a costly mistake.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The ASX is home to many dividend heavyweights
  • But CSL shares aren't usually considered among these
  • Here's why that assumption may be a mistake

 The CSL Limited (ASX: CSL) share price has been a staple of the S&P/ASX 200 Index (ASX: XJO) for decades now. In fact, CSL has spent its time over the past decade or so climbing up from the middle of the ASX 200 pack to the number three position on the Index that it now occupies.

But unlike its fellow top ASX 200 shares, such as BHP Group Ltd (ASX: BHP) or the big four banks, CSL has never been regarded as a dividend heavyweight. 

A quick look at the CSL share price today will probably tell you why. Right now, CSL has a trailing dividend yield of just 1.11%. That only comes partially franked too.

In stark contrast, BHP shares currently offer a fully-franked trailing yield of 8.86% right now. Commonwealth Bank of Australia (ASX: CBA) is at a fully-franked 4.2%, while Westpac Banking Corp (ASX: WBC) offers 5.62%.

So dividend-chasing income investors probably won't take too long in deciding which shares to have in their portfolios. But those investors might want to take a second look because all is not quite as it seems at first glance. 

Yes, you won't get as much dividend income upfront buying CSL shares as you would BHP or one of the big four banks. But CSL could well be a sleeping divided giant and one whose dividends might approach, or even exceed, the level of income offered by ASX's other heavyweights in just a few years.

Here's why.

A tired healthcare or lab worker sleeps on her desk

Image source: Getty Images

Why the CSL share price could be a sleeping dividend giant

CSL first started paying its investors dividends back in 2013. The company's very first dividend payment was a final dividend worth 52 US cents per share. In 2014, the company doled out annual dividend payments worth US$1.13 per share.

But just five years later in 2019, CSL was up to paying out US$1.85 in dividends per share. By 2022, this had risen again to a total of US$2.22 per share.

In US dollar terms, CSL has consistently raised its annual dividend every single year since 2013. Because of currency exchange rates, we can't say the same for its dividends in Aussie dollar terms. But the trend is clear.

In 2023 so far, this trend has continued too. The interim dividend that investors received only earlier this month came in at US$1.07 per share. That was a significant hike over 2022's corresponding payment of US$1.04 per share.

Between 2014 and 2022, CSL's annual dividend rocketed by a cumulative 96.5%. If CSL's dividends keep rising at this level over the next eight years, investors will be bagging US$4.36 in dividends per share by the year 2030. That's $6.54 per share in Australian dollars at the current exchange rate.

If that were to occur (which is by no means guaranteed), it would be highly lucrative for long-term investors, and would finally make CSL an ASX dividend heavyweight.

So this just proves that you can't judge an ASX divided share by the yield on its cover. By the time the 'sleeping giant' awakens, it might be too late to nab the shares at a good share price.

 

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended Westpac Banking. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Orthocell caps 26% surge this week with first US Military Surgery

The company's commercial rollout is off to a good start.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX health tech stock just hit a new record high. Could it go even higher?

Morgans believes there's still upside to be had.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Down almost 20% this year, how high could Mesoblast shares go?

The forward pipeline is looking promising.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares?

These three stocks might be too cheap to ignore.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Healthcare Shares

How much would $10,000 become if CSL shares returned to their record high?

After a sharp decline, CSL is in a new phase. The question is what happens next.

Read more »

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »